Diagnosis is difficult, and many cases are missed in everyday practice ...

Lewy body dementia (LBD) is a type of dementia caused by abnormal protein deposits in the brain, called Lewy bodies. The deposits cause chemical changes in the brain, leading to problems with thinking ...

Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...

Lewy body dementia (LBD) is a type of progressive disease that has affected more than a million Americans, according to the Lewy Body Dementia Association. Over time, it destroys brain cells and can ...

Neflamapimod, an experimental, oral drug targeting neuroinflammation being developed by CervoMed, led to a significant reduction in a key blood biomarker of neurodegeneration, which correlated with a ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Early detection of Alzheimer’s disease-related changes in Parkinson's disease and dementia with Lewy bodies could be made possible by monitoring the amyloid-β (Aβ) and phosphorylated tau (p-tau) ...

Investigators led by Tanya Simuni, MD, the Arthur C. Nielsen, Jr., Research Professor of Parkinson's Disease and Movement Disorders, have defined new biologic and clinical biomarkers for better ...

Parkinson's disease (PD), as well as many other neurodegenerative disorders, has shown a link between the abnormal aggregation of a protein called α-synuclein (aSyn) and neuronal death. These ...

Lewy body dementia is a progressive neurodegenerative disorder brought on by an excess of the protein alpha-synuclein in the brain. These deposits, known as Lewy bodies, can inhibit the production of ...